GBT440: Clinical Trials

16 trials of GBT440, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

10 completed, 4 terminated, 2 no longer available. 7 Phase 1, 3 Phase 2, 3 Phase 3, 1 Phase 4.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 6, Terminated 1
Phase 2	3	Completed 2, Terminated 1
Phase 3	3	Terminated 2, Completed 1
Phase 4	1	Completed 1

Follow GBT440: new trials by email Literature Review of GBT440 trials Research Report on GBT440

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Actigraphy Improvement With Voxelotor (ActIVe) Study Voxelotor - Sickle Cell Disease, Sickle Cell Anemia	Phase 4	Completed	Pfizer	25	2020-12-21	2023-11-21
Open-Label Extension of Voxelotor Voxelotor - Sickle Cell Disease	Phase 3	Terminated	Pfizer	162	2019-11-18	2025-11-13
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 Voxelotor - Sickle Cell Disease	Phase 3	Terminated	Pfizer	179	2018-06-06	2025-11-18
Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment GBT440 - Hepatic Impairment	Phase 1	Completed	Pfizer	29	2017-03-17	2023-07-18
Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions GBT440 - Cardio-pulmonary Function	Phase 1	Terminated	Global Blood Therapeutics	14	2016-12-01	2019-10-04
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) voxelotor, Placebo - Sickle Cell Disease	Phase 3	Completed	Pfizer	449	2016-12-01	2023-07-27
Single-Dose PK Study of GBT440 in Subjects With Renal Impairment GBT440 - Renal Impairment	Phase 1	Completed	Global Blood Therapeutics	16	2016-11-01	2018-02-22
Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest GBT440 - Idiopathic Pulmonary Fibrosis, Hypoxemia	Phase 2	Terminated	Global Blood Therapeutics	14	2016-11-01	2020-08-21
An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001 GBT440 - Sickle Cell Disease	Phase 2	Completed	Global Blood Therapeutics	5	2016-08-01	2019-01-02
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF GBT440, Placebo - Idiopathic Pulmonary Fibrosis, Hypoxemia	Phase 2	Completed	Global Blood Therapeutics	39	2016-06-01	2020-10-20
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects GBT440 - Sickle Cell Disease	Phase 1	Completed	Global Blood Therapeutics	24	2015-09-01	2017-04-12
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects GBT440 - Sickle Cell Disease	Phase 1	Completed	Global Blood Therapeutics	26	2015-09-01	2017-04-12
A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects GBT440 - Anemia, Sickle Cell	Phase 1	Completed	Global Blood Therapeutics	7	2015-06-01	2017-04-12
A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease GBT440, Placebo - Healthy Subjects, Sickle Cell Disease	Phase 1	Completed	Global Blood Therapeutics	133	2014-12-01	2018-02-15
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options Voxelotor - Sickle Cell Disease		No longer available	Pfizer			2024-11-20
Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options Voxelotor - Sickle Cell Disease		No longer available	Pfizer			2023-07-18

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding